Vivid Dx
PrivateLast Round
Seed
Jul 28, 2026
Total Funding Raised
$20.56M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Vivid Dx is a health tech company that develops a precision diagnostic platform for the rapid detection of sepsis-causing pathogens and antimicrobial resistance using Raman spectroscopy and AI-driven analysis.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware + Subscription, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivid Dx Comparables
Compare Vivid Dx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Resistell AG | 88% | |
| Astek Diagnostics | 87% | |
| iFAST Diagnostics | 86% |
Vivid Dx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jul 28, 2026 | ||||
| Grant | Apr 1, 2025 | ||||
| Early Funding | Apr 1, 2024 | ||||
| Grant | Dec 1, 2023 | ||||
| Grant | May 1, 2023 |
Vivid Dx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oxford Science Enterprises | Seed, Early Funding |
| JIMCO | Seed |
| Innovate UK | Grant |
| Cedars-Sinai Intellectual Property Company | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
$15M round led by Cedars-Sinai and Oxford Science Enterprises.
- Apr 20, 2026
Monthly visitors grew 75% MoM, reaching 2.4K.
Recent news
Latest coverage and updates
- hiresJul 28, 2026
Vivid Dx is planning to hire Keith O'Neill as chief executive officer.
- receives_financingJul 28, 2026
Vivid Dx received financing of $15M in Seed on Jul 28th '26.
- hiresJul 28, 2026
Vivid Dx hired Keith O'Neill as chief executive officer on Jul 28th '26.
Vivid Dx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vivid Dx's valuation, stock price, and market status.
Is Vivid Dx a public or private company?
Vivid Dx is a private company.
What is the current stock price of Vivid Dx?
Vivid Dx is a private company with no public stock price. No recent secondary market data is available.
How much is Vivid Dx worth (valuation)?
Valuation information for Vivid Dx is not publicly available.
Can I buy Vivid Dx stock?
Vivid Dx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vivid Dx's last funding round?
Vivid Dx's most recent funding round was Grant on April 1, 2025.
Who are the main investors in Vivid Dx?
Key investors in Vivid Dx include Oxford Science Enterprises.
Will Vivid Dx IPO soon?
No public IPO plans have been announced for Vivid Dx.
How can I track Vivid Dx secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vivid Dx's secondary market activity and sign up for updates.